
Daniel earned a Masters Degree in Transpersonal Counseling Psychology from Naropa and received advanced training in MDMA-assisted psychotherapy through a year internship with the MAPS Boulder MDMA for PTSD Study. It was his experience with MAPS that inspired Daniel to explore alternative visions in psychedelic activism and entrepreneurship. Daniel bridges transpersonal paradigms with the grounded clinical and organizational skills necessary to begin addressing the significant ecological and mental health crises facing our society today. Although Daniel no longer practices as a clinical psychotherapist, he supports his clients as a teacher, coach, ally and event facilitator, providing individual and group transformational experiences and deeply held intentional conversations. In his practice, Daniel quickly realized that the most important intervention he could provide to his clients, who were isolated and longed for meaningful contact with others, was a sense of community. Medicinal Mindfulness is, in a very real way, a cultural intervention that provides a safe and transformational community container for healing and awakening... a program based on skill development and not dogma. Since 2012, Daniel has been teaching a psychedelic harm prevention and intentional psychedelic use course called Mindful Journeywork. Since the legalization of recreational cannabis in Colorado, he has been facilitating Conscious Cannabis Circles and individual cannabis journeys.
In addition to his work with Medicinal Mindfulness, Daniel has a successful spirituality and life coaching practice with his wife, Alison, through their company, Aspenroots Counseling LLC. Highly skilled in identifying and cultivating giftedness in young people and supporting significant life transitions, Daniel is inspired to support passionate and talented individuals striving to live into their calling. A primary focus of his practice involves assessing and addressing the benefits and difficulties related to psychedelic and cannabis use and misuse. Daniel co-founded the Naropa Alliance for Psychedelic Studies and helped organize the first annual Psychedelic Symposium at Naropa University in 2012. He is currently working with Grounding Solutions, Inc. to develop a natural rescue medicinal for users of psychedelics and cannabis. daniel@medicinalmindfulness.org
Links Medicinal Mindfulness Aspen Roots Mental Health First Aid !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1400246380002879'); // Insert your pixel ID here. fbq('track', 'PageView'); fbq('track', 'ViewContent');
It has been a big week for psychedelic research. Psilocybin and MDMA have made national headlines. The New York Times article, "F.D.A. Agrees to New Trials for Ecstasy as Relief for PTSD Patients," highlights the recent win for MAPS in regards to their MDMA-assisted psychotherapy research. The FDA has given MAPS the green light to pursue phase 3 research for MDMA-assisted psychotherapy for post-traumatic stress disorder.
The New York Times also highlights the recent publications of psilocybin research in the article, "A Dose of a Hallucinogen from a 'Magic Mushroom,' and Then Lasting Peace." Psilocybin has been being researched by various institutions, including NYU and John Hopkins, for its potential therapeutic benefit to combat end-of-life anxiety due to terminal illness and cancer. The study results are fascinating: At the 6.5-month follow-up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60–80% of participants continued with clinically significant reductions in depression or anxiety), sustained benefits in existential distress and quality of life, as well as improved attitudes towards death. The psilocybin-induced mystical experience mediated the therapeutic effect of psilocybin on anxiety and depression. (http://m.jop.sagepub.com/content/30/12/1165.full)In this episode, Joe and Kyle chat with, Gabby Agin-Liebes, a co-author of the psilocybin study quoted above and a PhD student studying clinical psychology. During the conversation, we get into topics about the recent publication:
About Gabrielle Agin-Liebes: Ms. Agin-Liebes is completing her training toward a PhD in clinical psychology at Palo Alto University. She is a member of PAU’s Early Intervention Clinic clinical research laboratory, which provides and evaluates evidence-based treatments to prevent trauma-related problems in recently traumatized individuals. As part of this research laboratory, Ms. Agin-Liebes is examining the effects of trait self-compassion on trauma-related guilt cognitions. Through a supplemental practicum, Gabrielle is training toward a teacher certification in insight oriented mindfulness meditation through the Inner Resources Center at Palo Alto University. Ms. Agin-Liebes’ other research focuses on novel and progressive psychotherapies for a variety of clinical indications, with areas of specialty in anxiety, depressive and traumatic stress disorders precipitated by life threatening illnesses. Through the University of California San Francisco (UCSF) Ms. Agin-Liebes is co-leading the qualitative investigation of a pilot study examining the safety and feasibility of Psilocybin-Assisted Supportive-Expressive Group Psychotherapy for demoralization and existential distress in older individuals living with HIV. Prior to beginning her graduate studies, Gabrielle served as Project Manager of the NYU School of Medicine (NYUSoM) Psychedelic Research Laboratory led by Stephen Ross MD in the Department of Psychiatry, where she oversaw the day-to-day operations of trials exploring psilocybin as a treatment for existential distress in cancer patients, and ketamine as a rapidly-acting antidepressant in Emergency Department patients, Through the NYU School of Medicine lab, she has received funding to investigate the qualitative experiences of participants undergoing psilocybin treatment for alcohol dependence and is helping to design a qualitative trial of religious leaders receiving psilocybin at NYUSoM and Johns Hopkins University (JHU). Ms. Agin-Liebes’ other research interests include the role of self-compassion in addiction recovery and the therapeutic applications of meditation and mindfulness.
Download Joe and Kyle talk to Shannon Clare Petitt about the current state of MDMA research and what MAPS needs to do in the next number of months with the FDA as the phase three trials become approved. A few days after the interview the New York Times reported that the phase three research was approved. Shannon's story is great and optimistic. If you are interested in how to get a job in the psychedelic field, this is certainly an episode you'll want to listen to. We also discuss some possible tweaks to the studies that could be done that may yield interesting results, and also why MAPS is taking the approach that they are (its the most straightforward way to push the research through the FDA).
Here is Shannon's bio from the MAPS staff page. Links Psychedelic Salon Podcast Featuring Shannon, Rick Doblin and Annie Oak Zendo Project MAPS https://www.youtube.com/watch?v=nDzwFRbV9ggShannon Clare Petitt, M.A., MFTI, Therapist Training Program Coordinator and Zendo Project Community Engagement Coordinator
Shannon received her Master’s in Integral Counseling Psychology from the California Institute of Integral Studies in 2014, with a practicum working with youth on moderation management for drug and alcohol use. Her passions include working with addiction, trauma, relationship, the body, and nature. At the Multidisciplinary Association for Psychedelic Studies she serves as the Therapist Training Program Coordinator. She also leads Community Engagement for the Zendo Project, bringing harm reduction services to events and expanding efforts for awareness and integration of psychedelic experiences. Shannon is a co-therapist in a MAPS-sponsored Phase 2 trial researching MDMA-assisted psychotherapy for anxiety associated with life-threatening illness. She is a California native and can be found running outdoors anywhere she travels, dancing to the beat, and jumping in the ocean when she gets the chance!
Photo via Backcountry Cannabis[/caption] I hope you find his insights as interesting as we did. Feel free to reach out with any questions through our contact page or reach out to Faan via LinkedIn or Twitter - links below. In this interview we speak at length about number of subjects including:
In this episode Kyle and Joe speak about the recent interview they recorded with Dimitri Muganis. There were some relatively important points in the interview that needed further discussion and expansion and in this podcast we unravel some of the material. There is plenty more to unpack there. Some of what is discussed in this episode includes. In this interview, we discuss a lot, but here are some highlights.Brian Normand is Co-Founder of Psymposia, greenthumb, and occasional trouble maker, focused on creating spaces and projects to teach people about plants and drugs.
He graduated from the University of Massachusetts Amherst with a BS in Plant, Soil, Insect Science, & Sustainable Horticulture, Magna Cum Laude. He lives in Baltimore.
Kyle and Joe speak with Jonathan Thompson about his podcast Psychedelic Parenting and the future of the Psychedelic Parenting organization. Other topics that were covered include: The Aftercare Project is dedicated to the psychological and spiritual well-being of people reintegrating after challenging psychedelic experiences.The conversation is fun and wide ranging. We hope it is helpful and informative to academics, therapists, counselors and psychiatrists who are interacting with people coming back from difficult experiences. Here is a slightly longer description of the ACP.
Given the fact that ayahuasca has shown promise in research studies, we feel we not only have the humane duty to help those in need, but also the responsibility to ensure the reputation of ayahuasca and her traditional stewards among decision-makers in our own culture. This will allow us to continue holding space for research to continue, while protecting traditional practices. Because of the colossal challenges inherent in navigating multicultural spaces and the lack of understanding outside of the anthropological community regarding conflicting paradigms of urban capitalism and jungle reciprocity, we must do our best as North Americans to prepare those in our own communities who are called to this experience prior to their trip. This preparation will include full, informed consent, education on safety, cultural expectations and differences, and what to do in the case that further care is required upon return.Raven is also fundraising for the Aftercare Project. You can find a page for the fundraising effort here. Main site for Aftercare Project - Facebook
Lenny Gibson is a philosopher and clinical psychologist concerned with issues that bridge both disciplines:
- Practices that foster experiential understanding of philosophy, historically and contemporarily.
- Transpersonal psychology, particularly Holotropic Breathwork.